Every year, more than 70,000 people with sickle cell disease are admitted to hospitals. Rivipansel

(GMI-1070) is currently being studied as a potential treatment for vaso-occlusive crisis (VOC), the primary trigger for hospitalizations related to sickle cell disease.

At GlycoMimetics, we actively conduct promising research

and seek to establish unique collaborations in our pursuit of new treatments for people with serious diseases.

Patients with blood cancers have an urgent need for new medical treatment options. We recently began a clinical study of
GMI-1271.

Who We Are and What We Do

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.

GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline.

We are pleased now to be a public company traded on the NASDAQ under the symbol GLYC.

September is National Sickle Cell Disease
Awareness Month

stock-photo-10004105-fpo-sept

GlycoMimetics Honors the Sickle Cell Community

This month, and every month, GlycoMimetics honors those affected by sickle cell disease, their families, and their caregivers. As the discoverers of rivipansel (GMI-1070), an investigational drug which is currently being studied in partnership with Pfizer to treat vaso-occlusive crisis (VOC)—or pain crisis—of sickle cell disease, we recognize the critical need for more treatment options. We thank the sickle cell community for its ongoing commitment to educate and advocate on behalf of those impacted by the disease.